TABLE S1. Mutant frequency of the *cII* transgene in various organs of Big Blue mice chronically treated with 4-ABP or control (DMSO).

Treatment	Mouse ID	Total number of plaques $(pfu^*)$	Mutant plaques	Mutant frequency (x 10 <sup>-5</sup> )	Average mutant frequency (x 10 <sup>-5</sup> ) <sup>†</sup>	
		Bladder				
	238	321,250	6	1.87		
	239	985,000	23	2.34		
Control	240	850,000	16	1.88	$2.06 \pm 0.20$	
	241	436,250	9	2.06		
	251	1,080,000	25	2.31		
	229	1,030,000	149	14.47		
	230	1,050,000	198	18.86		
4-ABP (6 Weeks)	231	1,005,000	184	18.31	18.86 <u>+</u> 4.77	
	232	710,000	205	28.87		
	220	880,000	199	22.61		
	221	995,000	259	26.03		
(6 Weeks) D (6 Weeks)	222	1,255,000	202	16.10	17.20 4.00	
4-ABP (6 Weeks) + Recovery (6 Weeks)	223	1,030,000	249	24.17	17.20 <u>+</u> 4.88	
	247	1,330,000	172	12.93		
	248	1,070,000	184	17.20		
		Liver				
Control	238	540,000	11	2.04	2.04 ± 0.56	
	239	1,940,000	40	2.06	]	
	240	455,000	15	3.30	]	
	241	2,095,000	42	2.00		

	251	930,000	15	1.61	
	229	1,170,000	28	2.39	
	230	722,500	19	2.63	
4-ABP (6 Weeks)	231	1,095,000	52	4.75	4.54 <u>+</u> 1.08
	232	545,000	27	4.95	
	220	858,750	39	4.54	
	221	995,000	66	6.63	
	222	1,215,000	55	4.53	
4-ABP (6 Weeks) + Recovery (6 Weeks)	223	1,000,000	49	4.90	4.62 <u>+</u> 0.98
	247	1,170,000	54	4.62	
	248	1,100,000	39	3.55	
		Kidney			
	238	840,000	40	4.76	
	239	1,080,000	28	2.59	
Control	240	1,045,000	41	3.92	2.59 <u>+</u> 1.22
	241	1,280,000	15	1.17	
	251	566,250	14	2.47	
	229	1,330,000	33	2.48	
	230	880,000	34	3.86	
4-ABP (6 Weeks)	231	1,565,000	57	3.64	3.64 <u>+</u> 0.93
	232	785,000	41	5.22	
	220	1,095,000	31	2.83	
	221	1,195,000	62	5.19	
	222	1,195,000	31	2.59	
4-ABP (6 Weeks) + Recovery (6 Weeks)	ecovery (6 Weeks) 223 820,000		59	7.20	6.57 <u>+</u> 1.94
	247	1,150,000	96	8.35	
	248	700,000	46	6.57	

		Lung			
	238	1,200,000	43	3.58	
	239	1,045,000	37	3.54	
Control	240	1,035,000	29	2.80	$3.58 \pm 0.33$
	241	820,000	30	3.66	
	251	1,155,000	43	3.72	
	229	855,000	38	4.44	
	230	1,030,000	35	3.40	
4-ABP (6 Weeks)	231	1,555,000	37	2.38	3.07 <u>+</u> 0.69
	232	1,165,000	32	2.75	
	220	1,270,000	39	3.07	
4-ABP (6 Weeks) + Recovery (6 Weeks)	221	1,720,000	31	1.80	
	222	1,740,000	32	1.84	
	223	1,310,000	38	2.90	2.90 <u>+</u> 4.18
	247	935,000	122	13.05	
	248	483,750	17	3.51	
		Stomach			
	238	287,500	5	1.74	
	239	302,500	12	3.97	
Control	240	615,000	15	2.44	2.44 <u>+</u> 0.84
	241	895,000	20	2.23	
	251	410,000	15	3.66	
4-ABP (6 Weeks)	229	180,000	11	6.11	3.96 <u>+</u> 1.68
	230	675,000	11	1.63	
	231	530,000	21	3.96	
	232	485,000	14	2.89	

	220	323,750	19	5.87	
4-ABP (6 Weeks) + Recovery (6 Weeks)	221	455,000	18	3.96	
	222	945,000	31	3.28	
	223	805,000	23	2.86	3.39 <u>+</u> 1.30
	247	885,000	30	3.39	
	248	805,000	53	6.58	

Male adult Big Blue transgenic mice received weekly intraperitoneal injection of 4-ABP or control DMSO for a duration of 6 consecutive weeks, after which they were sacrificed either immediately, or after a 'Recovery' period of 6 weeks.

<sup>\*</sup> Plaque forming unit

 $<sup>^{\</sup>dagger}$ Results are expressed as median  $\pm$  95% CIs.

 ${\it TABLE~S2.} \ {\it Types~of~mutations~in~the~\it cII} \ {\it transgene~in~bladder~of~Big~Blue~mice~chronically~treated~with~4-ABP~or~DMSO~control.$ 

	Mutation	type	4-ABP	Control	4-ABP*	Control*
	Single mu	tation	143 (99.3%)†	138 (98.6%)	130 (92.2%)	100 (98.0)
Multiple mutations			1 (0.7%)	2 (1.4%)	1 (0.8%)	2 (2.0)
		Single	128 (88.9%)	105 (75.0%)	116 (88.5%)	80 (78.4%)
		AG→CT	0 (0%)	1 (0.7%)	0 (0%)	1 (1.0%)
	Tandem	TG→AT	1 (0.7%)	0 (0%)	1 (0.8%)	0 (0%)
Base substitution		CT→TG	1 (0.7%)	0 (0%)	1 (0.8%)	0 (0%)
	Multiple	$G \rightarrow T$ and $(T)$ Ins.	1 (0.7%)	0 (0%)	1 (0.8%)	0 (0%)
		$G \rightarrow A$ and $G \rightarrow A$	0 (0%)	1 (0.7%)	0 (0%)	1 (1.0%)
		$T \rightarrow A$ and $C \rightarrow T$	0 (0%)	1 (0.7%)	0 (0%)	1 (1.0%)
		Single	11 (7.6%)	16 (11.4%)	10 (7.6%)	13 (12.7%)
Deletion		Multiple	0 (0%)	1 (0.7%)	0 (0%)	1 (1.0%)
		Single	1 (0.7%)	15 (10.7%)	1 (0.8%)	5 (4.9%)
Insertion		Multiple	1 (0.7%)	0 (0%)	1 (0.8%)	0 (0%)

Male adult Big Blue transgenic mice received weekly intraperitoneal injection of 4-ABP or control DMSO for a duration of 6 consecutive weeks, after which they were sacrificed either immediately, or after a 'Recovery' period of 6 weeks.

\*Adjusted after exclusion of sibling mutations that occurred more than once at the same nucleotide position in the same animal.

†Percentage values are indicated in the brackets.

Ins. = Insertion

Del. = Deletion

TABLE S3. Comparative mutation spectra of the *cII* transgene in bladder of Big Blue mice chronically treated with 4-ABP or DMSO control.

Mutation type	Number of Mutations				% Mutations				Absolute Mutant Frequency (x 10 <sup>-5</sup> )			
	4-ABP	Control	4-ABP*	Control*	4-ABP	Control	4-ABP*	Control*	4-ABP	Control	4-ABP*	Control*
G:C→C:G	17	3	16 (8)	3	11.6	2.1	11.9 (6.0)	2.9	2.18	0.04	2.05 (1.03)	0.04
G:C→T:A	62	13	59 (14)	12 (4)	42.2	9.1	44.0 (10.4)	11.4 (3.8)	7.95	0.19	7.56 (1.79)	0.17 (0.06)
G:C→A:T	36	65	31 (14)	44 (35)	24.5	45.5	23.1 (10.4)	41.9 (33.3)	4.62	0.94	3.97 (1.79)	0.63 (0.50)
A:T→T:A	7	10	5	10	4.8	7.0	3.7	9.5	0.90	0.14	0.64	0.14
A:T→G:C	7	8	7	8	4.8	5.6	5.2	7.6	0.90	0.12	0.90	0.11
A:T→C:G	5	12	4	9	3.4	8.4	3.0	8.6	0.64	0.17	0.51	0.13
Del.	11	17	10 (2)	14	7.5	11.9	7.5 (1.5)	13.3	1.41	0.24	1.28 (0.26)	0.20
Ins.	2	15	2	5	1.4	10.5	1.5	4.8	0.26	0.22	0.26	0.07

Male adult Big Blue transgenic mice received weekly intraperitoneal injection of 4-ABP or control DMSO for a duration of 6 consecutive weeks, after which they were sacrificed either immediately, or after a 'Recovery' period of 6 weeks.

<sup>†</sup>Mutations occurring specifically at CpG dinucelotides are indicated in the brackets.

‡

Ins. = Insertion

Del. = Deletion

<sup>\*</sup> Adjusted after exclusion of sibling mutations that occurred more than once at the same nucleotide position in the same animal.

## Figure S1

**Distribution of mutations in the** *cII* **transgene in bladder of 4-ABP-treated mice and controls.** The spectra of mutations in the *cII* transgene in 4-ABP-treated mice and controls were established by DNA sequencing of mutants from bladder DNA of carcinogen-treated mice and controls, as described in 'Materials and Methods'. The 4-ABP-induced mutations are indicated above the reference *cII* sequence, whereas the control mutations are shown below the reference *cII* sequence.

5'-CpG-contating sequences are indicated by asterisks in control.




Fig. S1